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Insights Into Peptide Inhibition of
Alpha-Synuclein Aggregation
James H. Torpey1, Richard M. Meade2, Ravina Mistry1, Jody M. Mason2 and
Jillian Madine1*
1 Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom, 2 Department of Biology
and Biochemistry, University of Bath, Bath, United Kingdom
α-Synuclein (aSyn) aggregation is an attractive target for therapeutic development for
a range of neurodegenerative conditions, collectively termed synucleinopathies. Here,
we probe the mechanism of action of a peptide 4554W, (KDGIVNGVKA), previously
identified through intracellular library screening, to prevent aSyn aggregation and
associated toxicity. We utilize NMR to probe association and identify that 4554W
associates with a “partially aggregated” form of aSyn, with enhanced association
occurring over time. We also report the ability of 4554W to undergo modification through
deamidation of the central asparagine residue, occurring on the same timescale as
aSyn aggregation in vitro, with peptide modification enhancing its association with aSyn.
Additionally, we report that 4554W can act to reduce fibril formation of five Parkinson’s
disease associated aSyn mutants. Inhibitory peptide binding to partially aggregated
forms of aSyn, as identified here, is particularly attractive from a therapeutic perspective,
as it would eliminate the need to administer the therapy at pre-aggregation stages,
which are difficult to diagnose. Taken together the data suggest that 4554W could be
a suitable candidate for future therapeutic development against wild-type, and most
mutant aSyn aggregation.
Keywords: alpha-synuclein, electron microscopy, neurodegenerative disease, NMR, Parkinson disease, peptide
interaction, protein aggregation
INTRODUCTION
Neurodegenerative diseases, such as Parkinson’s disease (PD), are associated with the self-assembly
and aggregation of proteins (Goedert, 1999). They arguably represent one of the most significant
challenges to modern medicine; they are prevalent and, as yet, there are no tools available
to fight back against the gradual yet relentless progression of neurodegeneration. A range of
strategies targeting toxicity associated with protein aggregation are being investigated (Dehay
et al., 2015; Fields et al., 2019). These include the use of passive or active immunization (Lee
and Lee, 2016; Vaikath et al., 2019). Another strategy is reduction of protein expression or
enhancement of clearance mechanisms (Stefanis et al., 2019), together with methods to prevent
cell to cell transmission of misfolded proteins (Hasegawa et al., 2017). Targeting the aggregation
process directly presents an attractive therapeutic option and has been probed using chaperones
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(Arosio et al., 2016; Burmann et al., 2020) or via modulation
and inhibitor compounds (Singh et al., 2017; Pujols et al., 2018;
Peña-Díaz et al., 2019). The majority of drugs currently on the
market are small molecules, however there is an increasing level
of interest in the use of peptides as pharmaceuticals. Peptides are
generally more specific to a given target than small molecules
and thus are considered less likely to have prohibitive side-effects.
Many of the issues that have historically proved an impediment to
the clinical development of peptides (e.g., proteolytic degradation
and localization) are better understood and can now be
circumvented (Mason, 2010; Fosgerau and Hoffmann, 2015).
Peptides are particularly attractive to neurodegenerative research
associated with protein aggregation due to their potential to
impede these broad and shallow protein-protein interactions,
and therefore fibril formation. Some peptides have been shown
to form β-hairpin structures that can “cap” fibrils to prevent
the addition of further monomeric units and thus blocking
their elongation, as shown for amylin and α-synuclein (aSyn)
(Huggins et al., 2011). An alternative approach has been to inhibit
assembly on one side of the protein using N-methylated peptides
to prevent the formation of hydrogen bonds (Madine et al., 2008)
or using short peptides containing residues that prevent further
protein attachment (Kim et al., 2009). There is therefore great
interest in the development of new peptide-based inhibitors to
combat the toxicity of aggregation-prone proteins, such as aSyn
(Mason and Fairlie, 2015).
A 10-residue peptide candidate, 4554W (KDGIVNGVKA) has
been previously identified by an intracellular library-screening
technique, and showed a reduction in aSyn fibril formation
and reduced cytotoxicity (Cheruvara et al., 2015). However,
this work did not provide insight into the mode of action of
the peptide. The work presented here aimed to employ NMR
techniques to test the hypothesis that 4554W bound to aSyn,
and to identify key residues involved in the interaction. The
ability of 4554W to inhibit the fibrillation of PD-associated aSyn
mutants was also explored. It was found that 4554W associates
with partially aggregated forms of aSyn, preventing fibril
growth. This is appealing for further therapeutic development
since the mechanism need not inhibit the native function of
aSyn, and could be administered following identification of




The pRK172 aSyn expression construct (kindly gifted by Michel
Goedert) was freshly transformed into E. coli BL21 (DE3) cells,
using the heat-shock method. These cells were used to inoculate
1 mL of super optimal broth with catabolite repression (SOC)
(100 µg/mL ampicillin), which was grown at 37◦C with shaking
at 200 rpm for 8 h. 150 µL of this culture was used to inoculate
50 mL of minimal medium (Solution A: 12.5 g/L Na2HPO4,
7.5 g/L KH2PO4 pH 7.2; Solution B (for 1 L): 4 g glucose, 1 g
(15N) NH4Cl, 240 mg MgSO4·7H2O, 20 mg CaCl2·2H2O, 10 mg
thiamine), and grown at 37◦C overnight. This starter culture was
used to inoculate 1 L of minimal medium such that the starting
optical density at 600 nm (OD600) was 0.1, with growth at 37◦C
with shaking at 180 rpm until the OD600 reached 0.8. At this
point isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added
to the culture to a final concentration of 0.5 mM and the culture
was then incubated with shaking overnight at 18◦C. The cells
were harvested by centrifugation at 4,000 g for 20 min at 4◦C.
The cell pellets were snap frozen in liquid nitrogen (LN2) prior to
storage at−80◦C.
Site-Directed Mutagenesis of aSyn
The QuikChange II kit (Agilent Technologies) was used
according to the manufacturer’s instructions to prepare the six
PD-linked aSyn mutants (A30P, E46K, H50Q, G51D, A53T, and
A53E). The WT aSyn pRK172 expression construct was used
as the template and the reaction carried out according to the
manufacturer’s instructions with the primer sequences shown in
Supplementary Table 1. Successful mutagenesis was confirmed
by sequencing (Source Bioscience) and proteins expressed and
purified as for wild-type.
Purification of aSyn
Cell pellets were resuspended in 20 mL Buffer A [20 mM Tris-
HCl pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA)],
and lysed by pressure homogenization, followed by a single cycle
of ultra-sonication (30 s at 23 kHz). The lysate was incubated
at 85◦C for 10 min and then clarified by centrifugation at
18,000 g for 30 min at 4◦C. The clarified lysate was applied
directly to a 5 mL Q HiTrap anion exchange chromatography
column (GE Healthcare Life Sciences) pre-equilibrated with
Buffer A. Protein was eluted from the column via gradient elution
with Buffer B (Buffer A + 1M NaCl). aSyn elutes from the
column at approximately 300 mM NaCl. Fractions were analyzed
by SDS-PAGE, pooled and filtered through an Amicon Ultra-
15 centrifugal filter with a 30 kDa molecular weight cut-off
(MWCO) (EMD Millipore). The flow-through was collected and
applied to a 10 kDa MWCO centrifugal filter, and concentrated
to 10 mg/mL. Protein concentration was determined using UV
absorbance at 280 nm and purity assessed by SDS-PAGE and
mass spectrometry. aSyn was buffer exchanged into double-
distilled water (ddH2O) using a PD-10 desalting column (GE
Healthcare Life Sciences) and lyophilized. Lyophilized protein
was monomerised by resuspension in hexafluoroisopropanol
(HFIP) and thoroughly vortexed until transparent. The HFIP was
then evaporated under a stream of nitrogen and resuspended in
the required buffer.
Production and Purification of Peptides
4554W was synthesized using a Liberty Blue microwave peptide
synthesizer (CEM). The peptide was synthesized on a Rink amide
ChemMatrix resin (PCAS BioMatrix) employing Fmoc solid-
phase technique, with repeated steps of coupling-deprotection-
washing for each amino acid. The activator solution consisted of
26 g PyBOP in 100 ml DMF, and the deprotection solution was
20% Piperidine in DMF with the addition of 5% Formic acid to
prevent aspartamide formation of the peptide.
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The peptide was removed from the matrix by incubating
in cleavage solution (95% TFA, 2.5% Triisopropylsilane, and
2.5% water), on a shaker at 25◦C, for 4 h. The resin
was removed by filtration, and the peptide precipitated
using ice cold ether, with vortexing and centrifugation at
7,000 g for 3 rounds. The pellet was left overnight at
room temperature to completely dry, and purified by HPLC
using a Jupiter 4 µm Proteo C-18 90 Å reverse phase
semipreparative column.
The fractions of the HPLC peaks were examined by mass
spectroscopy, using a microTOF (Bruker Daltonics) to confirm
which fractions contained the purified peptide (Supplementary
Figure 1). Fractions, containing the peptide were pooled, and
lyophilised. The dry weight of the purified peptide was measured




NMR spectra were collected on a Bruker Avance III 800 MHz
spectrometer equipped with a TCI CryoProbe (Bruker) at 298
K in 5 mm glass tubes. Lyophilized aSyn and 4554W were
reconstituted in NMR buffer (10 mM sodium phosphate pH
7.0, 100 mM KF, 0.05% NaN3) with a final concentration of
5% D2O (v/v) to a final concentration of 50 µM and 1 mM,
respectively. Each experiment required multiple samples: 1 mM
4554W alone, 50 µM aSyn alone, 50 µM aSyn + 1 mM
4554W. 1D proton and WaterLOGSY spectra were collected on
each sample every day for 6 days. Spectra were also obtained
using aged peptide (following incubation with a flea at 37◦C
for 6 days) and aSyn fibrils (formed by incubation with a flea
at 37◦C for 7 days). The 1D proton spectra were collected
with 128 scans, 20 dummy scans, an acquisition time of 0.734
s, and a sweep width of 13.9456 ppm. WaterLOGSY spectra
were collected with 256 scans, 16 dummy scans, an acquisition
time of 0.729 s, and a sweep width of 14.0396 ppm. 1D and
WaterLOGSY spectra were compared in TopSpin 3.5 pl 7
(Bruker) with the control spectra to check for signs of binding.
The integral volume for peaks corresponding to the aromatic
region (6.5–9 ppm) and aliphatic region (0.5–4.5 ppm) were
calculated in Origin and added together to give the peak area per
spectra avoiding the water peak. Peak volumes were calculated
for spectra obtained for 4554W alone and 4554W plus aSyn
(following subtraction of aSyn alone). The difference between




Coherence Spectroscopy (HSQC) of
Peptides
4554W was dissolved in D2O at 1 mM. 1D proton and 1H-
13C HSQC spectra were collected freshly prepared and following
incubation at 37◦C with agitation for 6 days. 1D proton
spectra were collected with 128 scans, 100 dummy scans, an
acquisition time of 0.557 s, and a sweep width of 9.1877
ppm. 1H-13C HSQC spectra were collected with 16 scans, 16
dummy scans, an acquisition time of 0.100 s (1H) and 0.014s
(13C), and a sweep width of 10.0122 ppm (1H) and 65.0005
ppm (13C). Spectra were processed in TopSpin and analyzed
in CCPN Analysis.
Transmission Electron Microscopy
Hundred micrometer samples of aSyn were incubated in PBS
pH 7.4 alone, or in the presence of equimolar 4554W at
37◦C, with agitation with a flea for 1 week. 5µL of each
sample was mounted onto a carbon-coated copper grid for
2 min. Excess was blotted away, and grids stained with
4% uranyl acetate for 30 s. Images were collected on a
120 kV Tecnai G2 Spirit BioTWIN electron microscope
(FEI) with a SIS Megaview III camera. Image and fibril
length analysis was carried out using ImageJ and OriginLab,
with the scale bar on each image used as the length
reference. Four images were used for each analysis with
number of measurements included in each analysis shown in
Supplementary Table 2.
Mass Spectrometry Peptide Analysis
Fresh and aged 4554W samples were diluted to a concentration
of 1 pmol/µL in 50% acetonitrile, 0.1% formic acid and
infused at 5 µL/min onto the electrospray ionization (ESI)
source of an Orbitrap Fusion. Comparison of theoretical
and experimental m/z values showed that measurements
were accurate to 3 ppm. Asparagine deamidation was
probed using the corresponding 1Da mass shift, and the
proportion of asparagine deamidated was determined
through deconvolution of the isotope (13C) cluster peaks.
This was further confirmed through higher-energy C-trap
dissociation (HCD) MS-MS.
Thioflavin T Fluorescence
aSyn (WT, A30P, E46K, H50Q, G51D, A53T, and A53E)
were prepared in PBS pH 7.4 at a concentration of 100
µM alone and in the presence of 100 µM 4554W. Samples
were incubated at 37◦C with agitation for up to 1 week.
Samples were transferred to a 96-well black-walled, clear
bottom plate (Nunc) with 2 µM Thioflavin T and fluorescence
measurements taken using λex = 440 nm and λem = 490
nm on a Flexstation 3 microplate reader (Molecular Devices).
Each sample was measured in triplicate and the final volume
in each well was 50 µL. Data was processed and analyzed
using OriginLab. Statistical significance of the differences was
assessed using analysis of variance (ANOVA) with the Bonferroni
post hoc test.
Addition of 4554W to Pre-formed Fibrils
WT aSyn fibrils were formed by incubating 100 µM aSyn in PBS
pH 7.4 at 37◦C, with agitation with a flea for 1 week. 4554W was
added to equimolar concentration and samples further incubated
for 5 days at 37◦C with agitation with a flea. Thioflavin T
and transmission electron microscopy with image analysis were
carried out as described above.
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RESULTS
4554W Binds to ‘Partially Aggregated’
aSyn Species and Shows Increased
Binding Over Time
We carried out Heteronuclear single quantum coherence
spectroscopy (HSQC) experiments using 15N labeled aSyn alone
and in the presence of increasing concentrations of 4554W,
up to a 20:1 peptide:protein ratio. No changes in intensity
or chemical peak shifts were observed suggesting little or no
binding to “NMR observable” aSyn species (Supplementary
Figure 2A). We also observed that when aSyn alone or
aSyn plus 4554W was incubated for 6 days the resulting
spectra were the same irrespective of the presence or absence
of 4554W (Supplementary Figure 2B). This suggests that
4554W does not bind with significant affinity to aSyn species
within the NMR visible size range, i.e., oligomers of trimeric
or less. It also indicates that the presence of 4554W does
not alter the aggregation of these low-n aSyn oligomers,
with observed loss of signal upon incubation consistent with
aggregation. The peaks that remain correspond to the C-terminal
region which is predicted to be outside of the core region
of aSyn fibrils (Li et al., 2018) and may remain flexible
and therefore NMR accessible upon aggregation. From this
data we hypothesized that 4554W could be binding to a
larger species of aSyn than cannot be detected via HSQC
NMR experiments.
We therefore utilized 1D proton and WaterLOGSY (Water-
Ligand Observed via Gradient SpectroscopY) NMR experiments
to probe this hypothesis and observe interactions between
4554W and “NMR invisible” aSyn species. These experiments
were designed to observe an NMR spectrum of 4554W, with
association to aSyn resulting in a reduction in 1D signal as 4554W
becomes “NMR invisible.” WaterLOGSY is often employed as a
screening method to identify compounds that can interact with
proteins or other macromolecules and can be used to probe
binding affinities within the micromolar range. The experiment
works by transferring magnetization from the bulk solution to
the ligand which is then detected as the NMR signal (Dalvit
et al., 2000). When some of the ligand is associated with
protein, resonances from the bound ligand will be observed
with the opposite sign to that of the unbound, identified as
reduction in signal.
1D and WaterLOGSY data indicated some association
between 4554W and aSyn at day 0 observed as a difference
between the spectrum acquired for 4554W alone and that
acquired in the presence of aSyn (Figure 1). Additionally,
upon incubation for 6 days the observed difference increased,
suggesting enhanced binding over time. This can be seen in
the difference WaterLOGSY spectra obtained daily for up to
6 days (Supplementary Figure 3A), with greater peak areas
present in the difference spectra at day 6 compared with day
0 (Supplementary Figure 3B). We therefore propose that the
peptide “recognizes” and is able to bind to partially aggregated
aSyn species and functions to prevent their further aggregation.
FIGURE 1 | Association between 4554W and aSyn increases over incubation time. (A) 1D proton and (B) WaterLOGSY NMR spectra collected at day 0 and
following incubation for 6 days as shown. The integral volume for peaks corresponding to the aromatic region (6.5–9 ppm) and aliphatic region (0.5–4.5 ppm) were
calculated and added together to give the peak area per spectra avoiding the water peak. Peak volumes were calculated for 4554W alone (black) and
4554W + aSyn (red). The difference between the total integral volumes were calculated and plotted (right). A reduction in peak area between 4554W alone and
4554W + aSyn indicates association. The change in peak area is greater at day 6 than day 0 suggesting increased association upon incubation. Difference
WaterLOGSY spectra are shown in more detail in Supplementary Figure 3.
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4554W Becomes Modified Upon
Incubation
During the analysis of WaterLOGSY and 1D data we observed
changes in the 4554W spectrum over time (Supplementary
Figure 4). To probe this change further 1H-13C natural
abundance HSQC experiments of 4554W alone were performed.
The spectra revealed clear shifts in the position of the Cα and Cβ
peaks corresponding to the Asn residue (Figure 2A). Asn is prone
to deamidation, resulting in a mass shift of 1Da, and is detectable
by mass spectrometry (Yang and Zubarev, 2010). Fresh and aged
(pre-incubated for 6 days) 4554W, prepared under identical
conditions to those used in the NMR experiments, were analzed
by MS through direct infusion revealing a primary ion with the
m/z value 521.3079 corresponding to the 2+ species (Figure 2B).
The fresh 4554W sample gave a predominant peak of 521.3079,
with less abundant peaks at 521.8045 and 522.2999 which reflect
those ions containing 13C. In the aged sample the distribution of
these peaks was different, with the predominant peak being the
middle peak (521.8010). This suggests that partial deamidation
of the sample had occurred, and the first 13C peak of the
FIGURE 2 | Deamidation of 4554W upon incubation. (A) Natural abundance HSQC for fresh (black) and aged (red) 4554W shows a shift in Asn residue.
(B) Deamidation results in a mass shift of 1Da. Direct infusion mass spectrometry of fresh and aged 4554W showed a shift from primary ion with m/z value 521.3079
(fresh), with less abundant peaks at 521.8045 and 522.2999 reflecting ions containing 13C. The aged sample shows a different distribution of peaks, with the
predominant peak being the middle peak (521.8010). This suggests that partial deamidation has occurred, and the first 13C peak of the unmodified 4554W now
overlaps with that of the deamidated 4554W. By looking at the ratio in the relative abundances of each peak in the two samples it was possible to determine the
proportion of 4554W that had been deamidated to be approximately 50%. (C) Higher-energy collisional (HCD) MS-MS used to determine the location of
deamidation by generating ion fragments of 4554W. The distribution of peaks showing a dual population (observed as a preceding peak prior to the main peak, red
arrows) for the aged 4554W mimics that seen for the whole peptide at sites C-terminal to the modification site. The lack of preceding peaks in fresh 4554W (black
arrows), and loss of the preceding peak corresponding to N6 in the aged 4554W sample indicates that this is the site responsible for the dual population with a
difference in mass of 1Da.
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unmodified peptide superimposed with that of the deamidated
peptide (observed as + 0.5Da which corresponds to + 1Da in
the + 1 species). By observing the ratio of each peak’s relative
abundance in the two samples it was possible to determine
the proportion of 4554W that had been deamidated to be
approximately 50%. Using higher-energy collisional (HCD) MS-
MS (Olsen et al., 2007) the location of this deamidation was
determined. Unlike in Figure 2B in which m/z values of the
whole peptide were recorded, using HCD MS-MS ion fragments
of the peptide were generated. As can be seen in Figure 2C,
the distribution of peaks mimics that seen for the whole peptide
until Asn is removed (Figure 2C). The loss of the preceding
peak indicates that the Asn residue is responsible for the dual
population (with a difference in mass of 1Da). This corresponds
to the mass change induced by deamidation and confirms that
Asn 6 in the 10-residue peptide is the site of deamidation. This
data highlights that partial deamidation of Asn is taking place
within a similar timeframe to the aggregation of aSyn in vitro
and may be modulating the affinity of interaction between aSyn
aggregates and 4554W. The data suggests that greatest binding is
achieved between modified peptide and partially aggregated aSyn.
We collected WaterLOGSY NMR spectra using freshly
prepared 4554W and following aging to induce deamidation
in the presence of freshly prepared aSyn (presumed to be
predominantly monomeric) and using aSyn fibrils. Assessment
of the difference between 4554W alone and aSyn under
these different conditions (Supplementary Figure 5) confirms
that binding is enhanced following aging of the peptide,
and that greatest binding is observed between fibrillar aSyn
and aged 4554W.
4554W Prevents Aggregation of
PD-Associated Mutants
The initial peptide screen was designed to target the region
containing residues 45–54 of aSyn. This region contains all
but one (A30P) of the currently identified PD-associated aSyn
mutants (Meade et al., 2019). Here the ability of 4554W to
prevent fibrillation of mutant aSyn variants in vitro was explored.
Thioflavin T (ThT) was used to assess fibril formation of aSyn
variants in the absence and presence of equimolar concentrations
of 4554W. A significant reduction in ThT fluorescence was
observed in the presence of 4554W at day 3 for WT (p = 0.0003),
G51D (p = 0.0023) and A53T (p = 0.01082) (Figure 3). A53E
took longer to aggregate showing a significant reduction in ThT
fluorescence in the presence of 4554W by day 7 (p = 0.0216). In
contrast A30P, E46K, and H50Q had low ThT fluorescence after
7 days incubation and showed no significant reduction in the
presence of 4554W (Figure 3).
TEM analysis was used to observe changes in morphology of
fibrils formed following incubation for 1 week in vitro. WT, A30P,
H50Q, and A53T mutant aSyn variants form long fibrils when
incubated alone (Figure 4A). When incubated in the presence
of 4554W shorter fibrils/aggregate species were observed, with
length analysis confirming most species < 150 nm in length
(Supplementary Figure 6), and mean lengths significantly
reduced compared to the aSyn variants alone (Figure 5 and
FIGURE 3 | Thioflavin T fluorescence for aSyn variants alone and incubated in
the presence of 4554W. WT, G51D, A53T, and A53E show significant
reduction in ThT fluorescence upon incubation in the presence of 4554W.
Data is shown as mean ± SD for triplicate readings following incubation for 3
and 7 days. Control 4554W alone samples do not show any ThT fluorescence
(data not shown). *p < 0.05, **p < 0.01, ***p < 0.001.
Supplementary Table 2). In contrast, addition of 4554W had
little effect on the length of fibrils formed from E46K, G51D,
or A53E mutants (Figure 4B). G51D and A53E alone produced
short fibrils in comparison to WT and other mutant aSyn variants
with approximately 50% of fibrils measured < 100 nm.
4554W Disaggregates Pre-formed aSyn
Fibrils
Further to data showing 4554W preferentially associates with
aggregated aSyn species (Supplementary Figure 5), the ability
of 4554W to disaggregate pre-formed fibrils was probed.
Incubation of 4554W with pre-formed WT aSyn fibrils for
5 days showed no alteration in ThT fluorescence (Figure 6A).
However, TEM analysis showed a significant reduction in fibril
length (Figures 6B,C and Supplementary Figure 6) resulting in
fibrils of similar size to those produced when non-aggregated
aSyn is incubated in the presence of 4554W (as shown in
Figures 4A, 5). This indicated that 4554W can disaggregate
pre-formed aSyn fibrils. Taken together work presented here
showed that the presence of 4554W resulted in shortened fibrils
independent of the starting aSyn species, consistent with the
peptide acting to both prevent further aggregation and alter
pre-formed aggregates.
DISCUSSION
4554W was previously shown to inhibit fibrillation and reduce
cytotoxicity of aSyn showing potential biological and therapeutic
benefit for 4554W (Cheruvara et al., 2015). Here we showed that
4554W can bind to partially or fully aggregated species of aSyn
preventing further fibrillation and resulting in shorter fibrils. In
contrast no association is observed with monomeric aSyn. We
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FIGURE 4 | Transmission electron microscopy images for aSyn mutant proteins incubated alone and in the presence of 4554W. (A) WT, A30P, H50Q, and A53T
show significant reduction in fibril length upon incubation with 4554W. (B) E46K, G51D, and A53E do not show significantly altered length in the presence of 4554W.
Scale bar is 1µm.
report that maximal binding was achieved when 50% of 4554W
had undergone deamidation of the Asn 6 residue. Deamidation
can affect the structural integrity of proteins and peptides through
the introduction of a negative charge which may affect the
ability of 4554W to interact with aSyn and alter self-association
interactions. Given that deamidation occurred under in vitro
conditions that promoted aSyn aggregation we believe that
deamidation of the peptide would also occur in vivo if 4554W was
to be utilized in the future as a therapeutic option. However, an
alternative future strategy could involve synthesizing deamidated
4554W which may show improved association with aSyn.
Many avenues targeting aSyn aggregation are under
investigation as disease-modifying therapeutic approaches.
The small molecule inhibitor Fasudil has been shown to
prevent aggregation of aSyn by binding to the C-terminal
region identified via specific NMR chemical shifts (Tatenhorst
et al., 2016). In this study we report a lack of chemical shift
changes following addition of 4,454 W to aSyn showing
4554W doesn’t associate with monomeric asyn. The flavonoid
epigallocatechin gallate and phenol curcumin have shown
potential for inhibiting several aggregation-prone proteins
(Ehrnhoefer et al., 2008; Ahmad et al., 2017). They also act
via direct association to prevent the structural re-arrangement
required for fibril formation (Meng et al., 2009; Takahashi
et al., 2015). Other avenues being explored include the natural
antimicrobial, squalamine which has shown promise as an
inhibitor by competing with aSyn in binding lipid membranes,
specifically inhibiting aggregation initiation and in turn reducing
aSyn toxicity in cell and animal models of Parkinson’s disease
(Perni et al., 2017).
4554W is observed to reduce fibril formation assessed by
ThT or TEM against all known PD-associated mutants except
E46K. aSyn mutants that result in shorter fibrils when incubated
in the presence of 4554W (A30P, H50Q, and A53T) have
been previously shown to enhance the formation of oligomers
(Marvian et al., 2019). In contrast mutants that do not show an
effect on fibril length have been shown to have no effect (E46K)
or an inhibitory effect (G51D and A53E) on oligomer formation.
Morphological and structural similarities have also been observed
between WT, A30P, and A53T fibrils (Ruggeri et al., 2020). Recent
studies have shown that small molecules SynuClean-D and ZPD-
2 can reduce the aggregation of WT, H50Q, and A30P (Pujols
et al., 2018; Peña-Díaz et al., 2019). These mutants affect aSyn
oligomerization, therefore taken together data presented in this
study and previous data suggest that 4554W could be acting
during the oligomerization step targeting a common assembly
pathway in WT, A30P, H50Q, and A53T to modulate fibrillation.
G51D is associated with earlier age of onset, and a slower rate
of aggregation, therefore likely persisting in the oligomeric state
for longer than WT aSyn (Fares et al., 2014). This is consistent
with very few isolated patches of fibrils observed in our analysis.
In the presence of 4554W fibrils were more prevalent suggesting
that the presence of 4554W may influence G51D aSyn to follow
an alternative aggregation pathway that favors the formation of
amyloid fibrils, over that of oligomeric species. Therapeutically
this may be beneficial as fibrils may represent a benign endpoint.
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FIGURE 5 | Fibril length analysis for PD-associated aSyn mutants incubated
alone and in the presence of 4554W. Lengths of fibrils were measured from
TEM images as shown in Figure 4 in ImageJ using the scale bar on each
image as the length reference. Four images were analyzed for each condition.
Mean length of aggregates observed is shown as a horizontal line with the
median shown as a small square. Upper and lower limits of the boxes indicate
the 25th and 75th percentiles of the data, with “whiskers” indicating the 5th
and 95th percentile range of the data. A30P, H50Q, and A53T show
statistically significant (***p ≤ 0.0001) reduction in fibril length in the presence
of 4554W. The number of length measurements taken for each condition and
p-values are shown in Supplementary Table 2 with proportion of each
length fibrils shown in Supplementary Figure 6.
ThT fluorescence data for G51D suggests that oligomers that
form in the absence of 4554W have high ThT fluorescence
whereas fibrils produced in the presence of 4554W have lower
ThT fluorescence. A53E is the most recently identified PD-linked
point mutation in aSyn (Pasanen et al., 2014). It is thus the
least characterized with little known about its rate of aggregation
or fibril morphology. Here, we show that 4554W reduces ThT
fluorescence of A53E fibrils but has little effect on fibril length
assessed by TEM.
Interestingly, fibrils that show low ThT fluorescence with no
significant alteration in the presence of 4554W (A30P and H50Q)
show large fibrils with significant reduction by TEM. Whereas,
in contrast G51D and A53E show significant reduction in ThT
fluorescence with no show significant alteration in size by TEM. It
is known that aSyn mutants likely aggregate by different pathways
therefore it could be expected that 4554W may act on all mutants
in different ways either altering fibril morphology or amount of
fibrils formed. We report that mutants that do not show an effect
on ThT fluorescence in the presence of 4554W (A30P, E46K,
H50Q) had low ThT fluorescence in the absence of 4554W, in
comparison to those mutants that showed an effect. The low ThT
for these aSyn mutants alone may explain why a reduction in ThT
fluorescence in the presence of 4554W was not observed. We also
report that mutants that do not show a reduction in fibril length
(E46K, G51D, A53E) were smaller in the absence of 4554W, in
comparison to those mutants that showed an effect. This suggests
that 4554W is unable to reduce the length of mutants that already
produce short fibrils. We therefore hypothesize that 4554W acts
to reduce the length of long aSyn fibrils and to reduce ThT
fluorescence of aSyn species that have high fluorescence.
We also report that addition of 4554W to pre-formed fibrils
does not show a reduction in ThT fluorescence, whereas a
significant reduction in length was observed by TEM. We
hypothesize for pre-formed fibrils that the amount of fibrils
remains the same, whereas the morphology and length of the
fibrils is altered. Taken together this study highlights the need to
investigate multiple aspects of aggregation to generate a holistic
view of effect of addition of a potential aggregation inhibitor.
Data presented here is consistent with 4554W associating with
partially aggregated aSyn species. This work highlights a key
area of research that is hampered by a lack of reliable, readily
available techniques available to study interactions with partially
aggregated or oligomeric species directly. This barrier is largely
due to the transient nature of these aggregation intermediates
and the equilibrium that exists between monomeric, partially
aggregated and fully formed fibrils. Any attempt to isolate
aggregation intermediates to study their interactions causes
disruption to this equilibrium and could result in alteration
to the species present and an inaccurate representation of
what is happening in the native heterogeneous system. Future
experiments to probe association of 4554W with oligomeric
aSyn species could include ion mobility mass spectrometry
as utilized for a range of aggregating proteins (Woods et al.,
2013; Young et al., 2015), including aSyn (Liu et al., 2015).
Size exclusion chromatography enables isolation of oligomeric
species (Daturpalli et al., 2013; Schonhoft et al., 2017) and if
coupled with small angle X-ray scattering can provide structural
information (Rekas et al., 2010). Employing fluorescent or
other labeling approaches would also enable microscopy-based
methods to probe and visualize peptide-oligomer interactions.
We acknowledge that while we don’t present evidence for
direct binding the data we present confirms lack of binding
to monomeric aSyn and shows enhanced association upon
incubation of aSyn consistent with our conclusion.
The ability of a therapeutic to act after onset of symptoms in
neurodegenerative diseases associated with protein aggregation
is an important prerequisite for its use as a disease-modifying
therapy. This has been shown previously with anle138b able to
modulate oligomer formation and inhibit disease progression
in a Parkinson mouse model even when treatment was started
after disease onset (Levin et al., 2014). Previously identified
small molecules have been shown to have different modes of
action affecting different stages of aggregation, e.g., ZPD is
more effective at early stages of aggregation (Peña-Díaz et al.,
2019), whereas SynuClean-D can target later stages (Pujols
et al., 2018). Data presented here suggests that 4554W acts
following onset of aggregation and is able to disaggregate pre-
formed fibrils highlighting its potential for future therapeutic
development. Assessing the effect of 4554W on toxicity associated
with mutant aSyn aggregation was beyond the scope of the
current work. This represents the next stage in development
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FIGURE 6 | Incubation of pre-formed aSyn fibrils with 4554W. (A) No difference in ThT fluorescence was observed following incubation of pre-formed aSyn fibrils
with 4554W for 5 days. (B) TEM images show short fibrils upon incubation of pre-formed fibrils with 4554W. Scale bar 1 µM. (C) Lengths of fibrils measured from 4
images using the scale bar as the length reference show a significant reduction in mean length compared to fibrils incubated alone. Mean length of aggregates
observed is shown as a horizontal line with the median shown as a small square. Upper and lower limits of the boxes indicate the 25th and 75th percentiles of the
data, with “whiskers” indicating the 5th and 95th percentile range of the data. The number of length measurements and p-values are shown in Supplementary
Table 2 with proportion of each length fibrils shown in Supplementary Figure 6.
of 4554W as a future therapeutic to confirm the preliminary
data presented here highlighting its potential to alter WT and
mutant aSyn aggregation. Taken together with additional studies
as outlined above probing peptide-oligomer association, toxicity
evaluation is required to enable assessment of the effectiveness
of 4554W to reduce aggregation associated pathogenicity
when added at advanced stages of aggregation and future
therapeutic development.
Overall the data suggests that it may be feasible to target
aSyn variants with similar fibril morphological properties (WT,
A30P, H50Q, and A53T) by a single therapeutic strategy, instead
of requiring individual approaches for each PD-associated
mutation. The data also provides additional confirmation that
peptide therapeutics may be a feasible option for modulating
aSyn aggregation, and associated cytotoxicity. This is especially
attractive if they can be targeted to pre/partially-aggregated
species overcoming the need to administer them prior to signs
of disease onset.
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